Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
The efficacy and safety of rotigotine transdermal patch in Parkinson's disease (PD) were studied in some clinical trials. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy, tolerability, and safety of rotigotine transdermal patch versus...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3720658?pdf=render |
| _version_ | 1819213223260323840 |
|---|---|
| author | Chang-Qing Zhou Shan-Shan Li Zhong-Mei Chen Feng-Qun Li Peng Lei Guo-Guang Peng |
| author_facet | Chang-Qing Zhou Shan-Shan Li Zhong-Mei Chen Feng-Qun Li Peng Lei Guo-Guang Peng |
| author_sort | Chang-Qing Zhou |
| collection | DOAJ |
| description | The efficacy and safety of rotigotine transdermal patch in Parkinson's disease (PD) were studied in some clinical trials. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy, tolerability, and safety of rotigotine transdermal patch versus placebo in PD.Six randomized controlled trials (1789 patients) were included in this meta-analysis. As compared with placebo, the use of rotigotine resulted in greater improvements in Unified Parkinson's Disease Rating Scale activities of daily living score (weighted mean difference [WMD] -1.69, 95% confidence interval [CI] -2.18 to -1.19), motor score (WMD -3.86, 95% CI -4.86 to -2.86), and the activities of daily living and motor subtotal score (WMD -4.52, 95% CI -5.86 to -3.17). Rotigotine was associated with a significantly higher rate of withdrawals due to adverse events (relative risk [RR] 1.82, 95% CI 1.29-2.59), and higher rates of application site reactions (RR 2.92, 95% CI 2.29-3.72), vomiting (RR 5.18, 95% CI 2.25-11.93), and dyskinesia (RR 2.52, 95% CI 1.47-4.32) compared with placebo. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events.Our meta-analysis showed that the use of rotigotine can reduce the symptoms of PD. However, rotigotine was also associated with a higher incidence of adverse events, especially application site reactions, compared with placebo. |
| first_indexed | 2024-12-23T06:55:27Z |
| format | Article |
| id | doaj.art-c9a16ec6d6c54d119fecf564a7ed3897 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T06:55:27Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c9a16ec6d6c54d119fecf564a7ed38972022-12-21T17:56:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e6973810.1371/journal.pone.0069738Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.Chang-Qing ZhouShan-Shan LiZhong-Mei ChenFeng-Qun LiPeng LeiGuo-Guang PengThe efficacy and safety of rotigotine transdermal patch in Parkinson's disease (PD) were studied in some clinical trials. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy, tolerability, and safety of rotigotine transdermal patch versus placebo in PD.Six randomized controlled trials (1789 patients) were included in this meta-analysis. As compared with placebo, the use of rotigotine resulted in greater improvements in Unified Parkinson's Disease Rating Scale activities of daily living score (weighted mean difference [WMD] -1.69, 95% confidence interval [CI] -2.18 to -1.19), motor score (WMD -3.86, 95% CI -4.86 to -2.86), and the activities of daily living and motor subtotal score (WMD -4.52, 95% CI -5.86 to -3.17). Rotigotine was associated with a significantly higher rate of withdrawals due to adverse events (relative risk [RR] 1.82, 95% CI 1.29-2.59), and higher rates of application site reactions (RR 2.92, 95% CI 2.29-3.72), vomiting (RR 5.18, 95% CI 2.25-11.93), and dyskinesia (RR 2.52, 95% CI 1.47-4.32) compared with placebo. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events.Our meta-analysis showed that the use of rotigotine can reduce the symptoms of PD. However, rotigotine was also associated with a higher incidence of adverse events, especially application site reactions, compared with placebo.http://europepmc.org/articles/PMC3720658?pdf=render |
| spellingShingle | Chang-Qing Zhou Shan-Shan Li Zhong-Mei Chen Feng-Qun Li Peng Lei Guo-Guang Peng Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS ONE |
| title | Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. |
| title_full | Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. |
| title_fullStr | Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. |
| title_full_unstemmed | Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. |
| title_short | Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. |
| title_sort | rotigotine transdermal patch in parkinson s disease a systematic review and meta analysis |
| url | http://europepmc.org/articles/PMC3720658?pdf=render |
| work_keys_str_mv | AT changqingzhou rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis AT shanshanli rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis AT zhongmeichen rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis AT fengqunli rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis AT penglei rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis AT guoguangpeng rotigotinetransdermalpatchinparkinsonsdiseaseasystematicreviewandmetaanalysis |